Results of a Multicenter Open-Label Randomized Trial Evaluating Infusion Duration of Zoledronic Acid in Multiple Myeloma Patients (the ZMAX Trial)

James R. Berenson, Ralph Boccia, Timothy Lopez, Ghulam M. Warsi, Eliza Argonza-Aviles, Simone Lake, Solveig G. Ericson, Robert Collins

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Zoledronic acid, an intravenous (IV) bisphosphonate, is a standard treatment for multiple myeloma (MM) but may exacerbate preexisting renal dysfunction. The incidence of zoledronic acid-induced renal dysfunction may correlate with infusion duration. In this randomized, multicenter, open-label study, 176 patients with MM, at least one bone lesion, and stable renal function with a serum creatinine (SCr) level <3 mg/dL received zoledronic acid 4 mg (in 250 mL) as a 15- or 30-minute IV infusion every 3-4 weeks. At month 12, 20% (17 patients) in the 15-minute and 16% (13 patients) in the 30-minute arm experienced a clinically relevant but nonsignificant SCr-level increase (P = 0.44). By 24 months, the proportion of patients with a clinically relevant SCr-level increase was similar between arms (15-minute 28% [24 patients] vs 30-minute 27% [23 patients], P = 0.9014). Median zoledronic acid end-of-infusion concentrations were higher with the shorter infusion (15-minute 249 ng/mL vs 30-minute 172 ng/mL), and prolonging the infusion beyond 15 minutes did not influence adverse events related to zoledronic acid. For patients with MM, the safety profile of IV zoledronic acid is similar between those receiving a 15- or 30-minute infusion; therefore, determining the appropriate infusion duration of zoledronic acid should be based on individual patient considerations.

Original languageEnglish (US)
Pages (from-to)32-40
Number of pages9
JournalJournal of Supportive Oncology
Volume9
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

zoledronic acid
Multiple Myeloma
Creatinine
Kidney
Serum
Diphosphonates
Intravenous Infusions

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Results of a Multicenter Open-Label Randomized Trial Evaluating Infusion Duration of Zoledronic Acid in Multiple Myeloma Patients (the ZMAX Trial). / Berenson, James R.; Boccia, Ralph; Lopez, Timothy; Warsi, Ghulam M.; Argonza-Aviles, Eliza; Lake, Simone; Ericson, Solveig G.; Collins, Robert.

In: Journal of Supportive Oncology, Vol. 9, No. 1, 01.2011, p. 32-40.

Research output: Contribution to journalArticle

Berenson, James R. ; Boccia, Ralph ; Lopez, Timothy ; Warsi, Ghulam M. ; Argonza-Aviles, Eliza ; Lake, Simone ; Ericson, Solveig G. ; Collins, Robert. / Results of a Multicenter Open-Label Randomized Trial Evaluating Infusion Duration of Zoledronic Acid in Multiple Myeloma Patients (the ZMAX Trial). In: Journal of Supportive Oncology. 2011 ; Vol. 9, No. 1. pp. 32-40.
@article{6b93c4c3eb984c5480c8523c501bb07d,
title = "Results of a Multicenter Open-Label Randomized Trial Evaluating Infusion Duration of Zoledronic Acid in Multiple Myeloma Patients (the ZMAX Trial)",
abstract = "Zoledronic acid, an intravenous (IV) bisphosphonate, is a standard treatment for multiple myeloma (MM) but may exacerbate preexisting renal dysfunction. The incidence of zoledronic acid-induced renal dysfunction may correlate with infusion duration. In this randomized, multicenter, open-label study, 176 patients with MM, at least one bone lesion, and stable renal function with a serum creatinine (SCr) level <3 mg/dL received zoledronic acid 4 mg (in 250 mL) as a 15- or 30-minute IV infusion every 3-4 weeks. At month 12, 20{\%} (17 patients) in the 15-minute and 16{\%} (13 patients) in the 30-minute arm experienced a clinically relevant but nonsignificant SCr-level increase (P = 0.44). By 24 months, the proportion of patients with a clinically relevant SCr-level increase was similar between arms (15-minute 28{\%} [24 patients] vs 30-minute 27{\%} [23 patients], P = 0.9014). Median zoledronic acid end-of-infusion concentrations were higher with the shorter infusion (15-minute 249 ng/mL vs 30-minute 172 ng/mL), and prolonging the infusion beyond 15 minutes did not influence adverse events related to zoledronic acid. For patients with MM, the safety profile of IV zoledronic acid is similar between those receiving a 15- or 30-minute infusion; therefore, determining the appropriate infusion duration of zoledronic acid should be based on individual patient considerations.",
author = "Berenson, {James R.} and Ralph Boccia and Timothy Lopez and Warsi, {Ghulam M.} and Eliza Argonza-Aviles and Simone Lake and Ericson, {Solveig G.} and Robert Collins",
year = "2011",
month = "1",
doi = "10.1016/j.suponc.2010.12.002",
language = "English (US)",
volume = "9",
pages = "32--40",
journal = "The journal of supportive oncology",
issn = "1544-6794",
publisher = "Biolink Communications, Inc.",
number = "1",

}

TY - JOUR

T1 - Results of a Multicenter Open-Label Randomized Trial Evaluating Infusion Duration of Zoledronic Acid in Multiple Myeloma Patients (the ZMAX Trial)

AU - Berenson, James R.

AU - Boccia, Ralph

AU - Lopez, Timothy

AU - Warsi, Ghulam M.

AU - Argonza-Aviles, Eliza

AU - Lake, Simone

AU - Ericson, Solveig G.

AU - Collins, Robert

PY - 2011/1

Y1 - 2011/1

N2 - Zoledronic acid, an intravenous (IV) bisphosphonate, is a standard treatment for multiple myeloma (MM) but may exacerbate preexisting renal dysfunction. The incidence of zoledronic acid-induced renal dysfunction may correlate with infusion duration. In this randomized, multicenter, open-label study, 176 patients with MM, at least one bone lesion, and stable renal function with a serum creatinine (SCr) level <3 mg/dL received zoledronic acid 4 mg (in 250 mL) as a 15- or 30-minute IV infusion every 3-4 weeks. At month 12, 20% (17 patients) in the 15-minute and 16% (13 patients) in the 30-minute arm experienced a clinically relevant but nonsignificant SCr-level increase (P = 0.44). By 24 months, the proportion of patients with a clinically relevant SCr-level increase was similar between arms (15-minute 28% [24 patients] vs 30-minute 27% [23 patients], P = 0.9014). Median zoledronic acid end-of-infusion concentrations were higher with the shorter infusion (15-minute 249 ng/mL vs 30-minute 172 ng/mL), and prolonging the infusion beyond 15 minutes did not influence adverse events related to zoledronic acid. For patients with MM, the safety profile of IV zoledronic acid is similar between those receiving a 15- or 30-minute infusion; therefore, determining the appropriate infusion duration of zoledronic acid should be based on individual patient considerations.

AB - Zoledronic acid, an intravenous (IV) bisphosphonate, is a standard treatment for multiple myeloma (MM) but may exacerbate preexisting renal dysfunction. The incidence of zoledronic acid-induced renal dysfunction may correlate with infusion duration. In this randomized, multicenter, open-label study, 176 patients with MM, at least one bone lesion, and stable renal function with a serum creatinine (SCr) level <3 mg/dL received zoledronic acid 4 mg (in 250 mL) as a 15- or 30-minute IV infusion every 3-4 weeks. At month 12, 20% (17 patients) in the 15-minute and 16% (13 patients) in the 30-minute arm experienced a clinically relevant but nonsignificant SCr-level increase (P = 0.44). By 24 months, the proportion of patients with a clinically relevant SCr-level increase was similar between arms (15-minute 28% [24 patients] vs 30-minute 27% [23 patients], P = 0.9014). Median zoledronic acid end-of-infusion concentrations were higher with the shorter infusion (15-minute 249 ng/mL vs 30-minute 172 ng/mL), and prolonging the infusion beyond 15 minutes did not influence adverse events related to zoledronic acid. For patients with MM, the safety profile of IV zoledronic acid is similar between those receiving a 15- or 30-minute infusion; therefore, determining the appropriate infusion duration of zoledronic acid should be based on individual patient considerations.

UR - http://www.scopus.com/inward/record.url?scp=79955974622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955974622&partnerID=8YFLogxK

U2 - 10.1016/j.suponc.2010.12.002

DO - 10.1016/j.suponc.2010.12.002

M3 - Article

C2 - 21465735

AN - SCOPUS:79955974622

VL - 9

SP - 32

EP - 40

JO - The journal of supportive oncology

JF - The journal of supportive oncology

SN - 1544-6794

IS - 1

ER -